Company: CERO
Filing Date: 2025-07-21
Form Type: S-1
Source: 0001213900-25-066152
Chunk: 345

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-07-21
Form: S-1
Chunk 345
---
 following table summarizes
the shares of our Series A Preferred Stock issued to our related parties:

| Purchasers                              |     | Shares of          
 Series A Preferred 
 Stock              |       |     | Total    
 Purchase 
 Price    |           |
|:----------------------------------------|:----|:-------------------|------:|:----|:---------|----------:|
| Daniel Corey(1)                         |     |                    |   150 |     | $        |   150,000 |
| Atwood-Edminster Trust dtd 4-2-2000 (2) |     |                    | 1,002 |     | $        | 1,002,000 |
| Chris Ehrlich(3)                        |     |                    |   275 |     | $        |   275,000 |

F-29

On February 5, 2025, the Company announced the pricing of a reasonable
best efforts public offering (the “Offering”), with participation from a member of the Company’s board of directors
and a single institutional investor, for the purchase and sale of (i) shares of common stock, (ii) February 2025 Pre-funded
Warrants; and (iii) common warrants to purchase up to shares of common stock (the “February 2025 Common Warrants”),
at a combined public offering price of $ per share and Warrant (See Note 8).

The following table summarizes
the pre-funded warrants and February 2025 Common Warrants sold to our related party:

| Purchasers                                           |     | Pre-Funded Warrants Purchased |        |     | Total    
 Purchase 
 Price    |         |     | February 2025 Common Warrants Issued |        |
|:-----------------------------------------------------|:----|:------------------------------|-------:|:----|:---------|--------:|:----|:-------------------------------------|-------:|
| Atwood-Edminster Trust dtd 4-2-2000 and GVN, LLC (2) |     |                               | 25,510 |     | $        | 999,992 |     |                                      | 25,510 |

| (1) | Daniel Corey served as the Chief Technology Officer and a member of the board of directors of the Company from February 2024 to September 2024, and previously served as Chief Executive Officer, Chief Scientific Officer, and a member of the board of directors of Legacy CERo until the closing of the Business Combination in February